Sigma-Aldrich Acquires Seppro(R) Depletion Technology From GenWay Biotech
Sigma-Aldrich now offering antibody-based depletion columns and new catalog of
IgY antibodies to proteomics research community
ST. LOUIS, Mo., Jan. 6 /PRNewswire-FirstCall/ -- Sigma-Aldrich
(Nasdaq: SIAL) has expanded its proteomics offerings with the acquisition of
Seppro® affinity depletion technology and a library of 700 avian-derived
antibodies from GenWay Biotech, Inc. Seppro depletion products enable
scientists to measure more precisely the expression of protein biomarkers from
a range of mammalian and plant biological samples. This acquisition covers
current inventory, production technology and all future rights to produce and
distribute the product lines.
The Seppro IgY depletion platform is an antibody-based technology for
processing plasma, serum and plant samples. It enables researchers to detect
and analyze commonly obscured biomarkers in samples by removing highly
abundant proteins. Seppro depletion products are built using chicken-derived
IgY antibodies, providing higher selectivity and lower cross-reactivity than
other comparable products. The Seppro platform, incorporating SuperMix
technology, represents the most complete human depletion system available,
removing 14 of the most abundant proteins from human serum or plasma, as well
as other high and medium abundant proteins. Additional products are available
for the depletion of mouse and rat samples, as well as the industry's only
depletion system for the removal of Rubisco.
The library of 700 polyclonal IgY antibodies acquired from GenWay
represents Sigma-Aldrich's first IgY antibody offering. The new antibodies
are derived from chicken embryos and prepared using recombinant antigens.
Chicken antibodies display less cross-reactivity with mammalian proteins,
producing fewer false positive reactions in certain immunochemical assays.
Chicken IgY is also typically more stable than IgG derived from mammalian
species. With the acquisition of the chicken-derived IgY antibodies library,
Sigma-Aldrich also plans to expand its antibody catalog, to which more than
8,000 new antibodies were added in 2008.
"The acquisition of Seppro significantly strengthens Sigma-Aldrich's
position in antibody-based depletion technology," said Dr. Dave Smoller,
President of Sigma-Aldrich's Research Biotech Business Unit. "Our goal,
through acquisitions and collaborations, is to provide researchers with the
most comprehensive and highly characterized portfolio of antibodies and
Seppro technology joins Sigma-Aldrich's leading collection of depletion
products, including ProteoPrep® kits for the removal of highly abundant
proteins, such as albumin and IgG, from human serum and plasma. For more
information on Seppro, and all Sigma-Aldrich proteomics sample preparation
products, visit http://www.sigma-aldrich.com/genway.
About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company. Its biochemical and organic chemical products and kits are
used in scientific and genomic research, biotechnology, pharmaceutical
development, the diagnosis of disease and as key components in pharmaceutical
and other high technology manufacturing. The Company has customers in life
science companies, university and government institutions, hospitals, and in
industry. Over one million scientists and technologists use its products.
Sigma-Aldrich operates in 36 countries and has 8,000 employees providing
excellent service worldwide. Sigma-Aldrich is committed to Accelerating
Customer Success through innovation and Leadership in Life Science, High
Technology and Service. For more information about Sigma-Aldrich, please visit
its award-winning Web site at http://www.sigma-aldrich.com.
About GenWay Biotech: Genway Biotech Inc. is a diagnostic company based in
San Diego, CA that manufactures and supplies key components of diagnostic
kits, such as antibodies and antigens, to diagnostic companies. GenWay is
actively developing novel diagnostic tests for point-of-care and
over-the-counter diagnostics. GenWay specializes in immunoassay development,
applications, and manufacturing, as well as novel antibody platforms, such as
shark and chicken monoclonal antibodies, for increased sensitivity in
immunoassays and stability of diagnostic tests. For more information about
GenWay Biotech, please visit http://www.genwaybio.com.
Cautionary Statement: This release contains forward-looking statements
relating to future performance, goals, strategic actions and initiatives and
similar intentions and beliefs and other statements regarding the Companies'
expectations, goals, beliefs, intentions and the like, which involve
assumptions regarding the Companies' operations and conditions in the markets
the Companies serve. The Companies do not undertake any obligation to update
these forward-looking statements.
Sigma-Aldrich and ProteoPrep are registered trademarks of Sigma-Aldrich
Biotechnology L.P. and Sigma-Aldrich Co.
CONTACT: Sean Battles of Sigma-Aldrich, +1-314-286-7616,
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, email@example.com
Web site: http://www.sigma-aldrich.com